Skip to main navigation

AnaptysBio

Investor Relations

  • About
    • Overview
    • Strategy
    • Senior Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Contact
  • Science
    • Immune Cell Modulation
    • Publications
  • Pipeline
    • Overview
    • Rosnilimab
    • ANB032
    • ANB033
    • ANB101
    • Imsidolimab
    • Partnerships
  • Investors / News
    • Overview
    • News
    • Events
    • Presentations
    • Governance
    • Stock Information
    • Analyst Coverage
    • SEC Filings
    • Investor FAQs
    • Contact
  • Careers
    • Overview
    • Job Openings
    • Core Values
    • Total Reward Program Highlights
    • AnaptysBio Culture
  • Contact
Toggle

SEC Filing Details

SEC Filing Details

Document Details

Form
10-K
Filing Date
Mar 7, 2022
Document Date
Dec 31, 2021
Form Description
Annual report which provides a comprehensive overview of the company for the past year
Filing Group
Annual Filings
Company
AnaptysBio, Inc.
Issuer
ANAPTYSBIO, INC

Filing Formats

View HTML
Download PDF
Download DOC
Download XLS

XBRL

XBRL Viewer
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
EX-101.CAL - XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
EX-101.DEF - XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
EX-101.LAB - XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
EX-101.PRE - XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
XML - XBRL INSTANCE DOCUMENT

Tools

  • Print

    Print

  • Email

    Email

  • RSS Feeds

    RSS Feeds

  • Email Alerts

    Email Alerts

  • Investor Contact

    Investor Contact

  • Document Request

    Document Request

 

AnaptysBio, Inc.

10770 Wateridge Circle
Suite 210
San Diego, CA 92121-5801
(858) 362-6295 (ph)
(858) 362-6296 (fax)
info@anaptysbio.com
  • clear
  • clear

Quick Links

  • About
  • Science
  • Investors / News
  • Careers
  • Contact

Pipeline

  • Rosnilimab
  • ANB032
  • ANB033
  • Imsidolimab
  • Partnerships
© 2023 AnaptysBio, Inc. All Rights Reserved.
Privacy Policy  |  Terms Of Use